The DOI matches its Crossref record; 52 of the 52 references it cites were found in a registry or an index.
The Micro-Elimination Approach to Eliminating Hepatitis C: Strategic and Operational Considerations
Open accessAbstract
The introduction of efficacious new hepatitis C virus (HCV) treatments galvanized the World Health Organization to define ambitious targets for eliminating HCV as a public health threat by 2030. Formidable obstacles to reaching this goal can best be overcome through a micro-elimination approach, which entails pursuing elimination goals in discrete populations through multi-stakeholder initiatives that tailor interventions to the needs of these populations. Micro-elimination is less daunting, less complex, and less costly than full-scale, country-level initiatives to eliminate HCV, and it can build momentum by producing small victories that inspire more ambitious efforts. The micro-elimination approach encourages stakeholders who are most knowledgeable about specific populations to engage with each other and also promotes the uptake of new models of care. Examples of micro-elimination target populations include medical patients, people who inject drugs, migrants, and prisoners, although candidate populations can be expected to vary greatly in different countries and subnational areas.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Blach, S., Zeuzem, S., Manns, M., Altraif, I., Duberg, A.-S., Muljono, D. H., Waked, I., Alavian, S. M., Lee, M.-H., Negro, F., et al. (2017) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(16)30181-9 · Cited by 2,006
Self-citationPlatt, L., Easterbrook, P., Gower, E., McDonald, B., Sabin, K., McGowan, C., Yanny, I., Razavi, H., & Vickerman, P. (2016) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(15)00485-5 · Cited by 731
Self-citationVertical Transmission of Hepatitis C Virus: Systematic Review and Meta-analysis
Benova, L., Mohamoud, Y. A., Calvert, C., & Abu-Raddad, L. J. (2014) · Clinical Infectious Diseases · doi:10.1093/cid/ciu447 · Cited by 479
Glecaprevir and Pibrentasvir in Patients with HCV and Severe Renal Impairment
Gane, E., Lawitz, E., Pugatch, D., Papatheodoridis, G., Bräu, N., Brown, A., Pol, S., Leroy, V., Persico, M., Moreno, C., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1704053 · Cited by 400
Self-citationAspinall, E. J., Corson, S., Doyle, J. S., Grebely, J., Hutchinson, S. J., Dore, G. J., Goldberg, D. J., & Hellard, M. E. (2013) · Clinical Infectious Diseases · doi:10.1093/cid/cit306 · Cited by 309
Marrone, S. (2007) · International Journal of Circumpolar Health · doi:10.3402/ijch.v66i3.18254 · Cited by 264
Micro-elimination – A path to global elimination of hepatitis C
Lazarus, J. V., Wiktor, S., Colombo, M., & Thursz, M. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2017.06.033 · Cited by 234
Self-citationHepatitis C Treatment for Injection Drug Users: A Review of the Available Evidence
Hellard, M., Sacks‐Davis, R., & Gold, J. (2009) · Clinical Infectious Diseases · doi:10.1086/600304 · Cited by 232
Bruggmann, P., & Litwin, A. H. (2013) · Clinical Infectious Diseases · doi:10.1093/cid/cit271 · Cited by 184
Cited by
Karlsen, T. H., Sheron, N., Zelber-Sagi, S., Carrieri, P., Dusheiko, G., Bugianesi, E., Pryke, R., Hutchinson, S. J., Sangro, B., Martin, N. K., et al. (2022) · The Lancet · doi:10.1016/s0140-6736(21)01701-3 · Cited by 652
Self-citationBaliashvili, D., Blumberg, H. M., Gandhi, N. R., Averhoff, F., Benkeser, D., Shadaker, S., Gvinjilia, L., Turdziladze, A., Tukvadze, N., Chincharauli, M., et al. (2023) · PLOS Medicine · doi:10.1371/journal.pmed.1004121
Metadata
- Authors
- Safreed-Harmon, K., Thursz, M., Dillon, J., El-Sayed, M., Elsharkawy, A., Hatzakis, A., Jadoul, M., Prestileo, T., Razavi, H., Rockstroh, J., Wiktor, S., Colombo, M., & Lazarus, J.
- Venue
- Seminars in Liver Disease
- Publisher
- Georg Thieme Verlag KG
- Published
- 2018-07-09
- Volume
- 38
- Issue
- 03
- Pages
- 181-192
- ISSN
- 0272-8087 (ISSN-L)
- 1098-8971
- OpenAlex
- W2840933791
- Cited by
- 257
- References
- 52
- FWCI
- 17.60
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The Micro-Elimination Approach to Eliminating Hepatitis C: Strategic and Operational Considerations. https://app.cochat.ai/papers/10.1055/s-0038-1666841
- The paper
- Safreed-Harmon, K., Thursz, M., Dillon, J., El-Sayed, M., Elsharkawy, A., Hatzakis, A., Jadoul, M., Prestileo, T., Razavi, H., Rockstroh, J., Wiktor, S., Colombo, M., & Lazarus, J. (2018). The Micro-Elimination Approach to Eliminating Hepatitis C: Strategic and Operational Considerations. Seminars in Liver Disease. https://doi.org/10.1055/s-0038-1666841
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
